Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsSyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAzacitidineAnemia, SideroblasticBone MarrowChromosome AberrationsKaryotypingMonosomyThalidomidePreleukemiaMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesPancytopeniaAnemia, AplasticChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisTreatment OutcomeAcute DiseaseBone Marrow CellsLeukemiaChromosome DeletionGranulocyte Precursor CellsNeoplasms, Second PrimaryBone Marrow DiseasesHematopoietic Stem Cell TransplantationIron OverloadTrisomyAntimetabolites, AntineoplasticCytogeneticsErythrocyte TransfusionHematologic AgentsSurvival AnalysisTransplantation, HomologousHematopoietic Stem CellsChelation TherapyErythropoietinAntigens, CD34Blood TransfusionDown SyndromeRemission InductionMetabolic Syndrome XCytarabineTransplantation ConditioningBlast CrisisDisease ProgressionRetrospective StudiesBone Marrow ExaminationThrombocytopeniaMutationSurvival RateHematopoiesisBlood Cell CountVidarabineSweet SyndromeIn Situ Hybridization, FluorescenceAnemia, MacrocyticRisk FactorsGranulocyte Colony-Stimulating FactorHematologic DiseasesAntineoplastic AgentsChromosomes, Human, Pair 8AnemiaCore Binding Factor Alpha 2 SubunitChromosome DisordersHaploinsufficiencyKaryotypeErythroid Precursor CellsTranslocation, GeneticPrimary MyelofibrosisChromosomes, Human, Pair 20Hematologic NeoplasmsRecurrenceFollow-Up StudiesIron Chelating AgentsHematinicsLeukemia, Myelomonocytic, AcuteFlow CytometryFatal OutcomeErythroid CellsBone Marrow TransplantationErythroblastsHemoglobinuria, ParoxysmalImmunophenotypingDNA Modification MethylasesAntilymphocyte SerumBusulfanIsochromosomesHLA-DR Serological SubtypesAntineoplastic Combined Chemotherapy ProtocolsDNA Mutational AnalysisMyeloid Progenitor CellsErythropoiesisRibonucleoprotein, U2 Small Nuclear